COMMUNIQUÉS West-GlobeNewswire

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
20/07/2026
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients, SB11 provided functional and anatomical [...]
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
20/07/2026
- Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated - ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood [...]
Novo Nordisk A/S - share repurchase programme
20/07/2026
Bagsværd, Denmark, 20 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
20/07/2026
Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year SYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that [...]
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
20/07/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to include positive update [...]
Positron Secures Multiple PET-CT Orders Amid Accelerating Shift to Cardiac PET
20/07/2026
BUFFALO, NY, July 20, 2026 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leader in advanced molecular imaging technology and comprehensive PET imaging solutions, today announced [...]
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
20/07/2026
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study [...]
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
20/07/2026
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track [...]
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
20/07/2026
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using [...]
CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
20/07/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the filing of a new [...]
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
20/07/2026
President & CEO, Sabrina Martucci Johnson, to host interactive investor webcasts featuring corporate updates, commercial strategy and live Q&A SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( [...]
DLH to Announce Fiscal 2026 Third Quarter Financial Results
20/07/2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
20/07/2026
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting [...]
Vireo Growth Inc. to Acquire Certain Assets of The Cannabist Company Holdings Inc.
20/07/2026
Enters definitive agreement that expands its operations in one market and enters four additional states MINNEAPOLIS, July 20, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “ [...]
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
20/07/2026
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ramat Gan, Israel, [...]
BrainsWay Announces Strategic Investment in Radial Health, Inc.
20/07/2026
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, July 20, 2026 ( [...]
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
20/07/2026
LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
20/07/2026
Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program [...]
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
20/07/2026
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies [...]

Pages